Invivyd (IVVD) Other financing activities (2022 - 2025)
Invivyd's (IVVD) quarterly Other financing activities came in at $128.5 million in Q4 2025, up 95074.81% on a YoY basis from N/an in Q4 2024, and up 138.19% quarter-over-quarter from $53.9 million in Q3 2025.
Analysis
Invivyd (IVVD) Other financing activities (2022 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Other financing activities for 4 consecutive years, with $128.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other financing activities rose 95074.81% year-over-year to $128.5 million; the trailing twelve-month figure through Dec 2025 stood at $182.5 million (up 43360.48% YoY), and the FY2025 full-year result was $182.5 million, up 43360.48% from the prior year.
- Other financing activities advanced to $128.5 million in Q4 2025 per IVVD's latest filing, from $53.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $128.5 million in Q4 2025 and bottomed at $21000.0 in Q4 2022.
- Historically, Other financing activities has averaged $12.3 million across 4 years, with a median of $97000.0 in 2022.
- The sharpest annual moves came in 2023 and 2025: Other financing activities tumbled 63.92% in 2023, then soared 95074.81% in 2025.
- Over 4 years, Other financing activities stood at $21000.0 in 2022, then soared by 1071.43% to $246000.0 in 2023, then tumbled by 45.12% to $135000.0 in 2024, then jumped by 95074.81% to $128.5 million in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $128.5 million, $53.9 million, and $68000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 128.49 Mn |
| Sep 30, 2025 | 53.94 Mn |
| Jun 30, 2025 | 68,000.00 |
| Mar 31, 2025 | 37,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Sep 30, 2023 | 35,000.00 |
| Jun 30, 2023 | 215,000.00 |
| Mar 31, 2023 | 459,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 97,000.00 |
| Jun 30, 2022 | 76,000.00 |
| Mar 31, 2022 | 47,000.00 |